ABOUT US
PIPELINE
IR
COMMUNITY
ROCK Inhibitor–Based
Innovative Drugs for Degenerative Diseases
SCROLL DOWN
News
2026-05-18
Bichedam Completes Phase I Clinical Trial of BCD101, Demonstrating the Feasibility of Oral Puerarin Administration
2026-04-09
Saengmaeksan-gagambang Demonstrates Significant Improvement in Arterial Stiffness, Highlighting Its Potential as a Novel
[The Korean Medicine Newspaper] Clinical research demonstrating that Modified Saengmaeksan (BCD101) has positive effects on improving arterial stiffness in middle-aged women has ...
2026-04-08
Bichedam Launches Human Clinical Trial for ‘G Care’ to Verify Its Effectiveness in Improving Nocturnal Leg Cramps
Bichedam, a company specializing in natural product-based pharmaceuticals, announced on the 8th that it has initiated a human clinical study to evaluate the efficacy and safety...
2025-12-11
Gyeongsangbuk-do & Gyeongbuk TP Hold 2025 Gyeongbuk Regional Investment Forum
Gyeongsangbuk-do Province and Gyeongbuk Technopark (President Ha In-seong) held the 2025 Gyeongbuk Regional Investment Forum on the 10th at Laonjena Hotel ...
Saengmaeksan-gagambang Demonstrates Significant Improvement in Arterial Stiffness, Highlighting Its Potential as a Novel
2026-04-09
Bichedam Launches Human Clinical Trial for ‘G Care’ to Verify Its Effectiveness in Improving Nocturnal Leg Cramps
2026-04-08
Gyeongsangbuk-do & Gyeongbuk TP Hold 2025 Gyeongbuk Regional Investment Forum
2025-12-11
Bichedam Completes Phase I Clinical Trial of BCD101, Demonstrating the Feasibility of Oral Puerarin Administration
2026-05-18
COMPANY
BICHEDAM, a Korean biopharma developing natural, herbal-based treatments for hypertension, dementia, and other age-related diseases.
HISTORY
BICHEDAM’s ongoing growth, efforts, and plans since its founding in April 2022.
PARTNERS
BICHEDAM’s ongoing growth, efforts, and plans since its founding in April 2022.
Pipeline
Health Supplements
ROCK inhibitors show strong potential for treating
intractable neurodegenerative and cardiovascular diseases
through cytoskeletal reorganization, inflammation regulation, and neuroprotection.
ROCK inhibitors activating cytoskeletal, inflammatory, and neuroprotective mechanisms for refractory CNS and cardiovascular therapies.
Innovative Medicines
With a wide range of analytical technologies,
we provide customized analysis services tailored to our clients’ needs.
BICHEDAM Co., Ltd.
Head Office
Room 321, Korea Institute of Industrial Technology Research Center,
280 Daehak-ro, Gyeongsan-si, Gyeongsangbuk-do, Korea
Branch Office
Room 1516, Sky Valley 5th Building, 416 Hwagok-ro, Gangseo-gu, Seoul, Korea
CEO Hobin Moon
Email admin@bichedam.org
© 2025 BICHEDAM. All Rights Reserved.